T. Rowe Price Health Sciences PortfolioQAAGZX
Type
ETF
Peer group
US equity: Healthcare
Net assets
$662.6M
Expense ratio
0.85%
1-year return
+10.9%
3 years, a year
+5.8%
5 years, a year
+2.8%
Holdings
285
What it aims to do.
The fund seeks long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 10.21% |
| TMO Thermo Fisher Scientific Inc | 4.08% |
| ISRG Intuitive Surgical Inc | 3.68% |
| SYK Stryker Corp | 3.49% |
| MRK Merck & Co. Inc. | 3.46% |
| JOBY Astrazeneca Plc | 3.18% |
| UNH Unitedhealth Group Inc | 3.10% |
| ARGX Argenx Se - Adr | 2.93% |
| ABBV Abbvie Inc | 2.88% |
| REGN Regeneron Pharmaceuticals | 2.68% |
More on QAAGZX.
- QAAGZX overview
- QAAGZX holdings
- QAAGZX risk
- QAAGZX costs
- QAAGZX money in and out
- QAAGZX share classes
- Compare QAAGZX with other funds
Returns after fees, from the fund's SEC filings up to Mar 2026. Past returns are not a promise. Not financial advice.